Heparin Market Analysis & Forecast 2032

Heparin Market – Insights

Heparin is used to prevent or treat certain blood vessel, heart, and lung conditions. It is also used in blood transfusion, blood samplings during prophylaxis treatment, and for treatment of blood clotting disorders Heparin may be used to diagnose and treat a serious blood condition called disseminated intravascular coagulation. Heparin is sometimes used alone or in combination with aspirin to prevent pregnancy loss and other problems.

The global heparin market size was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).

Global Heparin Market Value (US$ Bn) & Y-o-Y Growth (%)

To learn more about this report, Request sample copy

Source: Coherent Market Insights Analysis (2019)

Increasing incidences of coronary heart disease, pulmonary embolism, and deep vein thrombosis is expected to drive growth of the heparin market

Heparin is widely used clinically for dialysis, deep vein thrombosis (DVT) treatment, and most cardiac surgeries. It is also used to prevent blood clotting during open-heart surgery, kidney dialysis, bypass surgery, and blood transfusions. Kidney dialysis procedure is increasing with rising chronic kidney disease, worldwide. For instance, according to Kidney Care UK 2016 report, about 3 million people in the U.K. are suffering from chronic kidney disease (CKD).

Furthermore, increasing number of surgeries and rising prevalence of diseases such as deep vein thrombosis and coronary heart disease, are fueling demand for heparin, eventually driving growth of the heparin market, during the forecast period. According to the American Heart Association 2018 report, coronary heart disease accounts for 1 in 7 deaths in the U.S., killing over 366,800 people every year. As per the same source, the overall prevalence for myocardial infarction (MI) in the U.S. is about 7.9 million, or 3 percent in U.S. adults.

Heparin Market Restraints

Side effects associated with the use of heparin are the major restraining factors of the market. The main side effect of heparin is bleeding. Heparin can cause spontaneous bleeding from several places in the body including open wounds or surgical sites, intestines and stomach, ovaries and uterus, and mouth and gums. Another serious side effect of heparin is a condition known as heparin-induced thrombocytopenia (HIT) in which heparin induces the body's immune system to develop antibodies against its own platelets, causing risk of bleeding due to reduction in platelets.

Heparin Market - Regional Insights

On the basis of region, the global heparin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe heparin market is expected to generate significant revenue share during the forecast period, owing to growing geriatric population and rising prevalence of long-term survivors of acute myocardial infarction (AMI). Survivors of AMI are at high risk of a recurrent myocardial infarction, as well as other manifestations of cardiovascular disease such as stroke. According to Lancet journal, 2017 report, acute myocardial infarction is the leading cause of hospital admissions and mortality in the UK and across the world.

Asia Pacific heparin market is expected to grow at the highest rate during the forecast period, owing to increasing incidence of myocardial infarction among regional population. According to a study published by National Center for Biotechnology Information (NCBI) in 2015, Asian population is more susceptible to MI than white people. There are 50% higher cases of MI in South Asians than in white people in the UK.

Global Heparin Market Share (%), By Region 2017

To learn more about this report, Request sample copy

 Source: Coherent Market Insights Analysis (2019)

Heparin Market - Competitive Landscape

Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.